Targeting SIRT1: A Potential Strategy for Combating Severe COVID‐19
Hajar Shokri-Afra, Fatemeh Saber Jeyvan, Zeinab Barartabar, Parisa Khanicheragh, Elham Yousefi Abdolmaleki, Davod Ilbeigi, Hadis Musavi, Yalda Malekzadegan · 2025
Read Targeting SIRT1: A Potential Strategy for Combating Severe COVID‐19 by Hajar Shokri-Afra, Fatemeh Saber Jeyvan, Zeinab Barartabar, Parisa Khanicheragh, Elham Yousefi Abdolmaleki, Davod Ilbeigi, Hadis Musavi, Yalda Malekzadegan (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12709655.txt.
Description
Hajar Shokri-Afra and co-authors review a protein as a drug target for severe COVID-19 in a 2025 paper. The protein, SIRT1, oversees inflammation, metabolism, and stress responses in cells. During infection with the virus that causes COVID-19, it shapes how the immune system reacts. The review gathers what is known about that role and what it could mean for treatment.
SIRT1 trims chemical tags from key gene switches and calms the cytokines that fuel the storm of severe illness. It also affects levels of ACE2, the cell surface dock the virus uses to enter. Natural compounds such as resveratrol, found in grapes, switch SIRT1 on more strongly. The authors argue that boosting this protein could support antiviral defense. They present it as a lead for new strategies against this and like viruses.
Catalog record
| CREATOR | Hajar Shokri-Afra, Fatemeh Saber Jeyvan, Zeinab Barartabar, Parisa Khanicheragh, Elham Yousefi Abdolmaleki, Davod Ilbeigi, Hadis Musavi, Yalda Malekzadegan |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |